Crowdonomics
All companies

Verax Research Services, Inc.

Operating

Biotech · Rockville, MD

Estimated pre-money ⓘ
$358.7M
As of Jun 2019 · from Reg A Offering (2019) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$525,000
Crowd $0 · Private $525K · 2 rounds since 2019
Latest share price
$6.25
Reg A Offering (2019) offering price

Financials

FY2018–FY2020 · from SEC filings · hover any figure for its source
$124K
−$389K
2018
$46K
−$632K
2019
$33K
−$1.1M
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 audited
FY2019 audited
FY2020 audited
Income statement
Revenue
$124,397
$46,273
$33,066
Cost of goods sold
$110,834
$134,006
$103,135
Gross margin
11%
-190%
-212%
Net income
-$388,581
-$631,900
-$1,085,251
Balance sheet
Cash
$11,374
$345,988
$3,050
Accounts receivable
$15,070
$0
$3,070
Total assets
$5,762,420
$6,045,481
$5,810,313
Long-term debt
$0
—
—
Total liabilities
$2,874,365
—
—
Other
Headcount
2
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$358.7M
est. pre-money
Reg A+ · Equity · Jun 2019

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Mar 5, 2020
ClassOutstandingVotes / shareShare of totalLast price
Common Stock57,375,000—100.0%—

Shares outstanding over timein today's share terms

57M29M0
Jun 2019Feb 2020
Common Stock

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $525KInvestors 3
Reg A+ · Equity · Jun 2019Failedvia DALMORE GROUP LLC
Raised $0 / $50MEst. pre-money $358.7M

Team

7 people
Garrett L. Lindemann (58)
Director, CEO
James Shaver (56)
Director of Operations
Fred Carlini (71)
Verax eMarketplace Corporate Quality Control and Compliance Officer
J. Randall Hoggle (63)
Chairman
Walter J. Skayhan (72)
Vice Chairman
William Bhodi Tims (62)
Cannacopeia Database and Scientific Director
Amy James (40)
Principal Financial Officer

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form DFeb 26, 20210001477932-21-001097
    EDGAR
  • Form 1-ZDec 30, 20200001477932-20-007566
    EDGAR
  • Form 1-A-WDec 30, 20200001477932-20-007568
    EDGAR
  • Form 1-USep 25, 20200001477932-20-005604
    EDGAR
  • Form 1-KSep 17, 20200001477932-20-005462
    EDGAR
  • Form 1-UJun 29, 20200001477932-20-003647
    EDGAR
  • Form 1-UMay 5, 20200001477932-20-002368
    EDGAR
  • Form 253G1May 5, 20200001477932-20-002367
    EDGAR
Source: SEC EDGARCIK 0001763987DEShare price $6.25Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.